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The global malaria eradication program of the
1950s and 1960s suffered serious setbacks in the
early 1970s, and the disease was slowly increasing
in areas of Asia and South America where the
number of cases had been reduced to low levels.
This article discusses malaria and, more
specifically, malaria in Africa, where the global
eradication program was never started and the
disease is reemerging at an alarming and
unprecedented rate.
The Disease
Malaria in humans is caused by a protozoon
of the genus Plasmodium and the four
subspecies, falciparum, vivax, malariae, and
ovale. The species that causes the greatest illness
and death in Africa is P. falciparum. The disease
is transmitted by the bites of mosquitoes of the
genus Anopheles, of which the Anopheles
gambiae complex (the most efficient) is respon-
sible for the transmission of disease in Africa.
Fever is the main symptom of malaria. The most
severe manifestations are cerebral malaria
(mainly in children and persons without previous
immunity), anemia (mainly in children and
pregnant women), and kidney and other organ
dysfunction (e.g., respiratory distress syndrome).
Persons repeatedly exposed to the disease acquire
a considerable degree of clinical immunity, which
is unstable and disappears after a year away from
the endemic-disease environment. Immunity
reappears after malarial bouts if the person
returns to an endemic-disease zone. Most likely to
die of malaria are persons without previous
immunity, primarily children or persons from
parts of the same country (e.g., high altitudes)
where transmission is absent, or persons from
more industrialized countries where the disease
does not exist.
Why Is Malaria Reemerging?
In the last decade, the prevalence of malaria
has been escalating at an alarming rate,
especially in Africa. An estimated 300 to 500
million cases each year cause 1.5 to 2.7 million
deaths, more than 90% in children under 5 years
of age in Africa (1). Malaria has been estimated to
cause 2.3% of global disease and 9% of disease in
Africa (1); it ranks third among major infectious
disease threats in Africa after pneumococcal
acute respiratory infections (3.5%) and tubercu-
losis (TB) (2.8%). Cases in Africa account for
approximately 90% of malaria cases in the world
(1). Between 1994 and 1996, malaria epidemics in
14 countries of sub-Saharan Africa caused an
unacceptably high number of deaths, many in
areas previously free of the disease (2).
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Adolescents and young adults are now dying of
severe forms of the disease. Air travel has
brought the threat of the disease to the doorsteps
of industrialized countries, with an increasing
incidence of imported cases and deaths from
malaria by visitors to endemic-disease regions.
The estimated annual direct and indirect costs of
malaria were US$800 million in 1987 and were
expected to exceed US$1.8 billion by 1995 (3).
      A number of factors appear to be contributing
to the resurgence of malaria: 1) rapid spread of
resistance of malaria parasites to chloroquine
and the other quinolines; 2) frequent armed
conflicts and civil unrest in many countries,
forcing large populations to settle under difficult
conditions, sometimes in areas of high malaria
transmission; 3) migration (for reasons of
agriculture, commerce, and trade) of nonimmune
populations from nonmalarious and usually high
to low parts of the same country where
transmission is high; 4) changing rainfall
patterns as well as water development projects
such as dams and irrigation schemes, which
create new mosquito breeding sites; 5) adverse
socioeconomic conditions leading to a much
reduced health budget and gross inadequacy of
funds for drugs; 6) high birth rates leading to a
rapid increase in the susceptible population
under 5 years of age; and 7) changes in the
behavior of the vectors, particularly in biting
habits, from indoor to outdoor biters.
What Knowledge Is Needed for Effective
Control?
Continental sub-Saharan Africa was never a
part of the global malaria eradication program.
The severity of the disease, the density and
efficiency of An. gambiae, the problem of
eradicating the disease over such a large land
mass with recurrent reinvasions, high costs, and
subsequent maintenance must have all contrib-
uted to the lack of will to undertake an
eradication program. Also, the eradication
program period coincided with the colonial and
immediate postcolonial period, during which
little or no indigenous capacity was available to
initiate and sustain malaria eradication. After a
period of laissez faire regarding malaria control,
these countries have had to face the reemergence
of the disease. Important questions about control
include the following. Is there enough knowledge
about the disease and its determinants? Are
there enough tools? Are existing resources
adequate? Are governments and populations of
endemic-disease countries adequately prepared?
Knowledge About the Disease and Its
Determinants
Falciparum malaria is a complex disease with
a patchy nonuniform distribution and clinical
manifestations that vary from one area to
another within an endemic-disease zone, often
showing space-time clustering of severe malaria
in the community (4). The relationship between
fevers, clinical disease, anemia, and cerebral
malaria remains the subject of current research.
The determinants of severe life-threatening
malaria need further elucidation. Present
research, focusing on the disease rather than the
infection and the dynamics of its transmission, is
bringing in new vision about the disease,
particularly the immunologic aspects. Persons with
asymptomatic parasitemia constitute an important
reservoir. The epidemiology of malaria (particu-
larly the relationship between the clinical patterns
of the disease in different locations, the pattern of
severe disease, and causes of deaths due to malaria)
needs future research (5).
Tools for Malaria Control
The present strategy for malaria control,
adopted by the Ministerial Conference on
Malaria in Amsterdam in 1992, is to prevent
death, reduce illness, and decrease social and
economic loss due to the disease (6). Its practical
implementation requires two main tools: first,
drugs for early treatment of the disease,
management of severe and complicated cases,
and prophylactic use on the most vulnerable
population (particularly pregnant women); sec-
ond, insecticide-treated nets for protection
against mosquito bites. Each tool has its own
problems in regard to field implementation.
Chloroquine remains the first-line therapy
for malaria. However, the alarming increase in
resistance in eastern and southern Africa
requires that sulfadoxine-pyrimethamine re-
place chloroquine as the first-line drug. Cur-
rently, 20% to 30% of strains are highly resistant
(RIII) with in vivo levels of 40% to 60%. Resistance
has been spreading westward, attaining levels of
20% to 35% in West Africa. Chloroquine remains
the drug of choice in most of sub-Saharan Africa.
      Resistance to mefloquine, another first-line
drug, developed in the early 1980s, was noticed
soon after its introduction and is now almost at400 Emerging Infectious Diseases Vol. 4, No. 3, July–September 1998
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the same level as chloroquine. Sulfadoxine-
pyrimethamine (Fansidar, Hoffman la Roche) is
the second-line drug in many countries of West
and Central Africa, but so much resistance
appears to be rising in countries of East Africa that
atovaquone/dapsone (Malarone, Glaxo Wellcome)
is being developed as a replacement. Intravenous
quinine is still the main therapy for cerebral
malaria, although resistance is increasing.
Development by the African strains of malaria
parasites of the pattern of drug resistance now
seen in Southeast Asia would be a major disaster.
More research is needed. For example, it is
necessary to initiate systematic monitoring of
drug resistance in Africa using standardized
methods. Drug efficacy studies using in vivo
methods have now been standardized by the
World Health Organization (WHO)/Regional
Office for Africa (AFRO) and carried out in a large
number of countries in West, Central, and East
Africa. Sentinel sites have also been established
for monitoring resistance. No new methods are
being developed. The feasibility of using
polymerase chain reaction techniques should be
explored. Also, management guidelines should be
developed concerning when and under what
conditions to change the treatment regimen for
different levels of resistance at the district,
regional, and central level. Development and
field testing of inexpensive, effective new malaria
drugs are urgently needed to replace present
drugs when resistance patterns make them
unusable. Drugs developed because of the more
serious problem of drug resistance in Asia should
be field tested in Africa. The most promising ones,
artemisinin and its derivatives artemether,
arteether, and artesunate, are being tested for
use in cerebral malaria and cases of proven
resistance to chloroquine (12); some are already
used in some countries.
Research carried out in Dakar (7) demon-
strated the efficacy of insecticide-treated nets for
reducing infant death; subsequent large-scale
multicenter studies in six countries across Africa
confirmed this finding (8-10). However, costs of
the nets and treatment still inhibit wide-scale
use. Ongoing research seeks ways of reducing
these costs, such as social marketing, possible
involvement of the private sector, cost-effective
methods for net treatment, the most appropriate
nets, and proper procurement of insecticides and
treatment of the nets. Eventually, the long-term
effects on natural acquisition of partial immunity
to malaria in endemic-disease areas should be
evaluated. The old vector-control method of house
spraying persists in some countries. The relative
merits and cost-effectiveness of house spraying
versus the use of treated nets should be evaluated.
The Challenge of Malaria Control to
Communities and Governments
The best tools will not necessarily lead to
malaria control. African populations have
traditional perceptions about disease causation
and management. Some diseases are considered
suitable for management by western medicine,
while others are considered the exclusive domain
of local traditional health practitioners. Deci-
sions to seek western medicine for any illness are
often considered a last resort.  Studies on health-
seeking behavior, perceptions of malaria, treat-
ments, and decision making for health care at the
household level are crucial to malaria control.
Such studies must be accompanied by improved
public awareness of the importance of seeking
appropriate treatment and complying with
recommended regimens.
Management of disease in the household
devolves on mothers. Fever remains the most
recognized symptom of malaria. Studies are
ongoing to determine the proportion of fevers
actually due to malaria. Mothers should be
taught to recognize the symptoms of malaria, to
provide home management, and to know when to
refer cases to health centers. Four countries in
Africa have developed and tested teaching guides
to facilitate home management of malaria (11).
Also, guidelines for the management of fever at
the periphery have been developed and field tested
within the Sick Child Initiative and have been
recommended for wide-scale application. Socioeco-
nomic and community studies are needed to
understand the extent to which the communities
will participate in new malaria control measures.
Finally, cost recovery of health care, including
costs of drugs (the Bamako Initiative), has been
the subject of many recent studies and probably
holds the key to health care in rural populations.
Some study results indicate an initial fall in
use of services following the introduction of cost-
recovery schemes (12). However, a recent study
indicates the opposite. Community health
workers were trained to administer prepackaged
antimalarial drugs only when paid. They also
received direct remuneration for their work
rather than being supported by the village on a401 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
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voluntary basis (13). This plan seems to have
increased attendance. This subject needs large-
scale multicenter studies.
Governments’ Response—Peripheral Health
Services
Health service organization, function, and
governing policies are important to malaria
control. Health policy and systems research have
been recently identified as neglected areas of
research in need of international effort (1). Many
studies are researching different ways to
integrate vertical malaria control programs into
the general health-care system. Economic
evaluation of different interventions is impor-
tant, and the techniques are continually being
refined and improved. They require much local
capacity since they tend to be country specific.
Studies in this area have now caught up with the
current trend favoring decentralization of
services, giving more power to the districts. Such
studies include ways of improving case manage-
ment where health services have been decentral-
ized, sustaining effective interventions, and
ensuring that drug supply chains function
optimally. Extensive research is examining
health sector reform on malaria control (12).
Health sector reform holds great potential for
controlling malaria and all other diseases, as it is
the focal point of the central and local
governments and the populations themselves.
Other needed research includes different health
policies, access to health services, and the issues
of equity in health care.
Is There a Place for Biomedical Research?
If the emphasis appears to be on epidemio-
logic and socioeconomic research and studies on
health policies and systems, it is because these
results have immediate importance  to malaria
control. The argument is for better use of existing
tools. However, tools alone will not provide all the
knowledge needed for sustainable malaria
control. Recent research by the Wellcome Trust
and the National Institutes of Health on
sequencing the genome of P. falciparum is likely
to lead to development of new antimalarial drugs
and vaccines. Similarly, DNA technologies are
being used to search for candidate molecules for
vaccines and new targets for drug development.
The development of a malaria vaccine is still
in the laboratories, and no effective vaccine is in
sight despite promising candidates. Subse-
quently, all candidate vaccine trials must be
closely linked to studies on how humans acquire
immunity and the correlation between protective
immunity and immunologic assays. Such studies
should be carried out longitudinally in multiple
sites where future vaccines will be tested.
On the vector side, studies in Mali have
shown that malaria transmission in this Sahel
country is maintained by a relay transmission
pattern, whereby the three main vectors appear at
different times of the year, thus ensuring that
vectors are always present (Y. Toure, pers. comm.).
More research is in progress concerning the
potential of using genetic engineering to make
the main malaria vector, An. gambiae, refractory
to the malaria parasite and releasing this refractory
parasite into the wild population to replace the
active vectors. Despite potential ethical problems,
this approach probably constitutes a long-term
future method for interrupting malaria transmis-
sion (14). Finally, the much-neglected issue of the
pathogenesis of malaria anemia both in children
and pregnant women, as well as the link of anemia
in pregnancy and HIV/AIDS, needs further study
and is likely to be multifactorial.
Mapping malaria transmission intensity
using geographic information systems and
geographic positioning systems has developed
into a Pan-African research collaboration for
Mapping the Malaria Risk in Africa, which has
received international funding. It plays a major
role in time-spatial mapping of malaria across the
continent with a strong potential for predicting
malaria epidemics (15) and monitoring control.
What Is the Response of the World Health
Organization?
WHO developed global and regional strate-
gies for malaria control after the Ministerial
Conference on Malaria in Amsterdam in 1992.
WHO/AFRO has multiplied efforts to encourage
countries to embark seriously on malaria control.
A WHO/AFRO Task Force for Malaria comprising
a selected sample of malaria control managers,
malaria experts from Africa, and technical
representatives from bilateral and multilateral
agencies funding malaria control in Africa was
set up in 1994. This task force has met regularly
to provide guidance on malaria control strategies
and to recommend criteria for monitoring and
evaluation as well as operational research. Some
of these agencies have recently increased their
malaria control funding directly to some402 Emerging Infectious Diseases Vol. 4, No. 3, July–September 1998
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countries of Africa; others have preferred funding
through the regional office.
In addition, the WHO Director General made
a generous grant of US$10 million from the WHO
regular budget for 1997 for intensified malaria
control efforts. Momentum is building, strongly
supported by the World Bank, for more concerted
efforts at malaria control.
The Way Forward
The Multilateral Initiative on Malaria in
Africa (MIM) was created in Dakar in January
1997 from the realization that success in
controlling malaria in the future would be greatly
enhanced by cooperation and collaborative
efforts in research to support strategies for
control (5). MIM capitalized on the important
1992 Ministerial Conference, which led to the
adoption of a Global Plan of Action for Malaria
Control and the World Health Assembly Resolution
on this subject (WHA 49.11), urging increased
efforts on malaria control. Composed of scientists
from Africa and their colleagues from industrial-
ized countries as well as representatives from major
funding agencies, MIM plans to facilitate collabora-
tion between governments, research scientists,
research funding agencies, and the private
(pharmaceutical industry) sector for concerted
action through research to combat malaria.
Like other diseases of low-income countries,
malaria has been grossly underfunded. From
1990 to 1992, $58 million a year was spent on
malaria research, while $56 billion was spent on
health research worldwide. Expressed as re-
search investment per death, malaria research
receives about US$42 per fatal case, much less
than for other diseases such as HIV/AIDS
(US$3,270) and asthma (US$789) (3). Rather
than the duplicative efforts of the past, MIM
encourages a common goal with common
research priorities, which should create a greater
spirit of cooperation.
Strengthening Research Capability
MIM took a firm stand on indigenous capacity
building for malaria research in Africa, an
important prerequisite for sustainable research
and control of malaria in that continent. Training
would be carried out in Africa as far as possible
but not exclusively so. Training would be carried
out for all health-care workers within the malaria
research and control pyramid, including Ministry
of Health personnel and those in research
institutes and universities, with no exclusion.
Flexible training programs would be developed to
meet the needs of individual research centers and
countries. A good start has been made. Using
funds provided late in 1997 to WHO’s Tropical
Diseases Research Programme, a task force was
set up for Malaria Research Capability Strength-
ening in Africa. The money funded North/South
and South/South collaborative research in
malaria. All the principal investigators were to be
from Africa. Training was central to the projects
so that more hands-on and practical research
training would be given to trainees, and practical
refresher training and technology transfer would
be given to experienced scientists.
Research centers also need to be strength-
ened. Laboratories need refurbishing and
equipment and supplies (including computer
equipment and software), and vehicles are
needed for field studies. Suitable research
careers should be created to encourage the best
scientists to remain in research.
Because scientific isolation constitutes a
major constraint to African scientists, communi-
cation facilities need urgent attention. One of
MIM’s highest priorities is to enhance the capacity
of African scientists to communicate electronically
with each other and with colleagues around the
world and to access needed scientific information
from local and remote libraries and the Internet.
NIH’s National Library of Medicine is playing a
lead role in this critical area.
The Future
Malaria is an important social, economic, and
developmental problem affecting individuals,
families, communities, and countries. The best
chance for successfully combating the disease
requires a collaboration particularly of those
responsible for control and research. Such
collaboration, particularly between South and
North, is being actively developed, and MIM
presents itself as a worthwhile initiative (16).
Important factors are 1) placing the control
strategy on a strong research base, 2) strong
international collaboration, and 3) sustained
government support.
Smallpox was eradicated because of the
development of freeze-dried vaccine, the develop-
ment of the multiple-use nozzle jet injector and
bifurcated needle, and the replacement of mass
vaccination by selective vaccination, coupled
with a strong international effort. Onchocercia-403 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
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sis is being controlled because research results
were immediately applied to control. Translat-
ing research findings into control methods has
also been pursued for Chagas disease and
leprosy. Concerted action between the research
and control communities is needed to ensure
that malaria follows the same path. MIM
strongly advocates this approach. Research
must be a constant feature throughout the
entire process of malaria control.
Dr. Nchinda is senior health specialist at the
Global Forum for Health Research based at the World
Health Organization headquarters in Geneva. His
research interests are in tropical diseases research
and control, particularly malaria, training and
utilization of health personnel, research capacity
strengthening, health services research, and organi-
zation of community health services.
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